Embecta Corp (EMBC) financials

NASDAQ · Health Care

$6.25 -4.73% Close Oct 30, 2026 Live

Embecta revenue and earnings by year

Embecta's revenue was $1.08 billion in the fiscal year to September 30, 2025, down 3.8% from the year before. Net income was $95.4 million, 8.8% of revenue. Since the fiscal year to September 30, 2019, revenue has shrunk 0.4% a year on average.

RevenueNet income
$500M$1.00B
2019202020212022202320242025

Fiscal years, each labelled by the calendar year it ended in.

Income statement, the last 7 fiscal years

In billions of US dollars except per-share figures. Each column is a fiscal year, named by the month it ended.
Fiscal year toSep 2025Sep 2024Sep 2023Sep 2022Sep 2021Sep 2020Sep 2019
Revenue1.081.121.121.131.171.091.11
Revenue growth-3.8%0.2%-0.8%-3.1%7.4%-2.1%—
Gross profit0.680.740.750.770.800.760.79
Gross margin62.6%65.5%66.9%68.6%68.7%70.3%70.9%
Operating income0.240.170.220.310.490.490.50
Operating margin22.4%14.9%19.8%27.4%42.2%44.8%45.3%
Net income0.100.080.070.220.410.430.43
Net margin8.8%7.0%6.3%19.8%35.6%39.4%39.0%
Diluted EPS$1.62$1.34$1.22$3.89———
Free cash flow0.180.020.040.390.420.460.44

Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open EMBC in Markets.

How Embecta makes money

Revenue by segment in the quarter to June 30, 2026, as the company reports it.

SegmentRevenueShare
Pen Needles$178M65.3%
Safety$36.7M13.5%
Syringes$36.6M13.5%
Product & Service Other$15.6M5.7%
Manufacturing Facility$5.30M2.0%

See also: EMBC valuation and P/E history · EMBC returns

No forecast, no recommendation. This page describes Embecta Corp from published data; it is not advice to buy, sell or hold any security.

Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.